Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911627 | 1.00 | GPR119 (0.44) | GPR119UCHL1USP30KDM1AHDAC1 | |
| SCHEMBL30120744 | 0.88 | GPR119 (0.45) | GPR119UCHL1USP30KDM1AHDAC1 | |
| SCHEMBL24344110 | 0.88 | GPR119 (0.43) | GPR119UCHL1USP30KDM1AHDAC1 | |
| SCHEMBL868434 | 0.88 | GPR119 (0.45) | GPR119UCHL1USP30KDM1AHDAC1 | |
| SCHEMBL30935296 | 0.86 | USP30 (0.35) | GPR119UCHL1USP30KDM1ABACE1 | |
| SCHEMBL1284165 | 0.84 | UCHL1 (0.44) | GPR119UCHL1USP30KDM1AHDAC1 | |
| SCHEMBL29534683 | 0.84 | UCHL1 (0.44) | GPR119UCHL1USP30KDM1AHDAC1 | |
| SCHEMBL23042880 | 0.84 | NOTUM (0.37) | GPR119NOTUM | |
| SCHEMBL30697868 | 0.83 | ESR2 (0.37) | GPR119UCHL1USP30KDM1ANOTUM | |
| SCHEMBL30697875 | 0.83 | ESR2 (0.37) | GPR119UCHL1USP30KDM1ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382488-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382488-A1 | NEK7 INHIBITORS | NEK7, NEK11, NEK2 | GPR119 876/4885UCHL1 4099/4885USP30 2698/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | GPR119 260/4885UCHL1 962/4885USP30 1907/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | GPR119 260/4885UCHL1 962/4885USP30 1907/4885 |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | ATF4, MAP3K10, EEF2K | GPR119 799/4885UCHL1 3455/4885USP30 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.